Hot topics in autoimmune diseases: Perspectives from the 2013 Asian Congress of Autoimmunity

Autoimmunity Reviews

Volumn 13, Issue 8, 2014, Pages 781-787

  Selmi, Carlo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Monoclonal antibody; Serum autoantibody; Tolerance breakdown

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; EARLY DIAGNOSIS; HONG KONG; HUMAN; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

MONOCLONAL ANTIBODY; SERUM AUTOANTIBODY; TOLERANCE BREAKDOWN;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; INFLAMMATION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902156053     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.05.006     Document Type: Review

References (94)

1. Agmon-Levin N., Mosca M., Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev 2012, 11:593-595.
2. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun 2013, 41:1-5.
3. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012, 39:249-252.
4. Meda F., Folci M., Baccarelli A., Selmi C. The epigenetics of autoimmunity. Cell Mol Immunol 2011, 8:226-236.
5. Stefan M., Zhang W., Concepcion E., Yi Z., Tomer Y. DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J Autoimmun 2013, 50:33-37.
6. Svendsen A.J., Hjelmborg J.V., Kyvik K.O., Houen G., Nielsen C., Skytthe A., et al. The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs. J Autoimmun 2013, 41:120-125.
7. Walker L.S. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 2013, 45:49-57.
8. Altorok N., Sawalha A.H. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2013, 25:569-576.
9. Debniak T., Soczawa E., Boer M., Rozewicka-Czabanska M., Wisniewska J., Serrano-Fernandez P., et al. Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk. Arch Dermatol Res 2014, 306:231-238.
10. Bohm B., Burkhardt H., Uebe S., Apel M., Behrens F., Reis A., et al. Identification of low-frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization. Arthritis Res Ther 2012, 14:R84.
11. Perricone C., Ciccacci C., Ceccarelli F., Di Fusco D., Spinelli F.R., Cipriano E., et al. TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics 2013, 65:703-709.
12. Pennell L.M., Galligan C.L., Fish E.N. Sex affects immunity. J Autoimmun 2012, 38:J282-J291.
13. Lleo A., Oertelt-Prigione S., Bianchi I., Caliari L., Finelli P., Miozzo M., et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun 2013, 41:87-91.
14. Sciascia S., Ceberio L., Garcia-Fernandez C., Roccatello D., Karim Y., Cuadrado M.J. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 2012, 12:157-163.
15. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni Bocci E., Carubbi F., et al. Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2013, 10.1016/j.jaut.2013.10.002.
16. Zhu Q., Liu M., Dai L., Ying X., Ye H., Zhou Y., et al. Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev 2013, 12:1123-1128.
17. Boettler T., Pagni P.P., Jaffe R., Cheng Y., Zerhouni P., von Herrath M. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. J Autoimmun 2013, 44:40-48.
18. Iorio R., Fryer J.P., Hinson S.R., Fallier-Becker P., Wolburg H., Pittock S.J., et al. Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun 2013, 40:21-27.
19. Katzav A., Arango M.T., Kivity S., Tanaka S., Givaty G., Agmon-Levin N., et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun 2013, 45:24-30.
20. Sinico R.A., Di Toma L., Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 2013, 12:477-482.
21. Schwartz N., Su L., Burkly L.C., Mackay M., Aranow C., Kollaros M., et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006, 27:242-250.
22. Sandling J.K., Garnier S., Sigurdsson S., Wang C., Nordmark G., Gunnarsson I., et al. A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur J Hum Genet 2011, 19:479-484.
23. Miret C., Font J., Molina R., Garcia-Carrasco M., Filella X., Ramos M., et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001, 21:3053-3059.
24. Agmon-Levin N., Theodor E., Segal R.M., Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013, 45:256-266.
25. Pludowski P., Holick M.F., Pilz S., Wagner C.L., Hollis B.W., Grant W.B., et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 2013, 12:976-989.
26. Yang C.Y., Leung P.S., Adamopoulos I.E., Gershwin M.E. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 2013, 45:217-226.
27. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117.
28. Bermejo D.A., Jackson S.W., Gorosito-Serran M., Acosta-Rodriguez E.V., Amezcua-Vesely M.C., Sather B.D., et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 2013, 14:514-522.
29. Dias P.M., Banerjee G. The role of Th17/IL-17 on eosinophilic inflammation. J Autoimmun 2013, 40:9-20.
30. Axtell R.C., Raman C., Steinman L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol 2013, 44:114-120.
31. Chong W.P., Horai R., Mattapallil M.J., Silver P.B., Chen J., Zhou R., et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun 2013, 50:12-22.
32. Garris C.S., Wu L., Acharya S., Arac A., Blaho V.A., Huang Y., et al. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol 2013, 14:1166-1172.
33. Hirota K., Turner J.E., Villa M., Duarte J.H., Demengeot J., Steinmetz O.M., et al. Plasticity of Th17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol 2013, 14:372-379.
34. Kim J.S., Sklarz T., Banks L.B., Gohil M., Waickman A.T., Skuli N., et al. Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol 2013, 14:611-618.
35. Raychaudhuri S.P. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013, 44:183-193.
36. Wang G., Tam L.S., Li E.K., Kwan B.C., Chow K.M., Luk C.C., et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 2010, 37:2516-2522.
37. Liu Y., Yin H., Zhao M., Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin. Rev. Allergy Immunol. 2013.
38. Zhu F.G., Jiang W., Bhagat L., Wang D., Yu D., Tang J.X., et al. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity 2013, 46:419-428.
39. Mok M.Y., Huang F.P., Ip W.K., Lo Y., Wong F.Y., Chan E.Y., et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 2010, 49:520-527.
40. Yanaba K., Muroi E., Yoshizaki A., Hara T., Ogawa F., Shimizu K., et al. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. J Rheumatol 2009, 36:1917-1923.
41. Wen J., Xia Y., Stock A., Michaelson J.S., Burkly L.C., Gulinello M., et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun 2013, 43:44-54.
42. Toledano P., Sarbu N., Espinosa G., Bargallo N., Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013, 12:1166-1170.
43. Peart E., Clowse M.E. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol 2014, 26:118-123.
44. Atzeni F., Sarzi-Puttini P., Mutti A., Bugatti S., Cavagna L., Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013, 12:1115-1117.
45. Leardini G., Rigon C. The impact of the profile of biologics on treatment costs. Autoimmun Rev 2013, 12:842-847.
46. Olivieri I., D'Angelo S., Padula A., Leccese P., Nigro A., Palazzi C. Can we reduce the dosage of biologics in spondyloarthritis?. Autoimmun Rev 2013, 12:691-693.
47. Atzeni F., Talotta R., Salaffi F., Cassinotti A., Varisco V., Battellino M., et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013, 12:703-708.
48. Cuadrado M.J., Sciascia S., Bosch X., Khamashta M.A., Ramos-Casals M. Is it time for biosimilars in autoimmune diseases?. Autoimmun Rev 2013, 12:954-957.
49. Mendes de Abreu M., Strand V., Levy R.A., Araujo D.V. Putting the value into biosimilar decision making: the judgment value criteria. Autoimmun Rev 2014, 13:678-684.
50. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12:436-443.
51. Mayer C.T., Huntenburg J., Nandan A., Schmitt E., Czeloth N., Sparwasser T. CD4 blockade directly inhibits mouse and human CD4(+) T cell functions independent of Foxp3(+) Tregs. J Autoimmun 2013, 47:73-82.
52. Podojil J.R., Liu L.N., Marshall S.A., Chiang M.Y., Goings G.E., Chen L., et al. B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. J Autoimmun 2013, 44:71-81.
53. Van Belle T.L., Ling E., Haase C., Bresson D., Urso B., von Herrath M.G. NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes. J Autoimmun 2013, 40:66-73.
54. Cutolo M., Nadler S.G. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013, 12:758-767.
55. Romo-Tena J., Gomez-Martin D., Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 2013, 12:1171-1176.
56. Maiti A.K., Nath S.K. Gene network analysis of small molecules with autoimmune disease associated genes predicts a novel strategy for drug efficacy. Autoimmun Rev 2013, 12:510-522.
57. Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013, 44:149-156.
58. Mitra A., Fallen R.S., Lima H.C. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2013, 44:173-182.
59. Zhang P., Zhao M., Liang G., Yin G., Huang D., Su F., et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun 2013, 41:17-24.
60. Arias-Loste M.T., Bonilla G., Moraleja I., Mahler M., Mieses M.A., Castro B., et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 2013, 45:109-116.
61. Spadaro A., Riccieri V., Sili Scavalli A., Sensi F., Taccari E., Zoppini A. Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis. Clin Rheumatol 1996, 15:218-219.
62. Spadaro A., Riccieri V., Sili Scavalli A., Sensi F., Fiore D., Taccari E., et al. Interleukin-6 and soluble interleukin-2 receptor in juvenile chronic arthritis: correlations with clinical and laboratory parameters. Rev Rhum 1996, 63:171-177.
63. Caetano-Lopes J., Rodrigues A., Lopes A., Vale A.C., Pitts-Kiefer M.A., Vidal B., et al. Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression. Clin. Rev. Allergy Immunol. 2013.
64. Taylan A., Sari I., Akinci B., Bilge S., Kozaci D., Akar S., et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012, 13:191.
65. Daoussis D., Liossis S.N., Solomou E.E., Tsanaktsi A., Bounia K., Karampetsou M., et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158.
66. Soumelis V. NRP-1 and IL-17-producing NKT cells. Blood 2011, 118:2934-2935.
67. Stebbings S.M., Taylor C., Tannock G.W., Baird M.A., Highton J. The immune response to autologous bacteroides in ankylosing spondylitis is characterized by reduced interleukin 10 production. J Rheumatol 2009, 36:797-800.
68. Comarmond C., Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 2013, 12:752-757.
69. Gualtierotti R., Biggioggero M., Meroni P.L. Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol 2013, 44:51-56.
70. Meijide H., Sciascia S., Sanna G., Khamashta M.A., Bertolaccini M.L. The clinical relevance of IgA anticardiolipin and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 2013, 12:421-425.
71. Viall C.A., Chen Q., Liu B., Hickey A., Snowise S., Salmon J.E., et al. Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. J Autoimmun 2013, 47:45-57.
72. Hahn B.H., Grossman J., Chen W., McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28:69-75.
73. Andreoli L., Fredi M., Nalli C., Franceschini F., Meroni P.L., Tincani A. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity 2013, 46:302-306.
74. Tam L.S., Kitas G.D., Gonzalez-Gay M.A. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?. Rheumatology 2014.
75. Tam L.S., Shang Q., Kun E.W., Lee K.L., Yip M.L., Li M., et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis-a randomized, placebo-controlled pilot trial. Rheumatology 2014.
76. Rosenfeld M.E. Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr Opin Pharmacol 2013, 13:154-160.
77. Bizzaro N., Antico A., Platzgummer S., Tonutti E., Bassetti D., Pesente F., et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev 2014, 13:292-298.
78. Agmon-Levin N., Damoiseaux J., Kallenberg C., Sack U., Witte T., Herold M., et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014, 73:17-23.
79. Perricone C., Colafrancesco S., Mazor R.D., Soriano A., Agmon-Levin N., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 2013, 47:1-16.
80. Cerpa-Cruz S., Paredes-Casillas P., Landeros Navarro E., Bernard-Medina A.G., Martinez-Bonilla G., Gutierrez-Urena S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res 2013, 56:299-303.
81. Cruz-Tapias P., Agmon-Levin N., Israeli E., Anaya J.M., Shoenfeld Y. Autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA)-animal models as a proof of concept. Curr Med Chem 2013, 20:4030-4036.
82. Vera-Lastra O., Medina G., Cruz-Dominguez Mdel P., Jara L.J., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol 2013, 9:361-373.
83. Israeli E. Gulf War syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvant (ASIA). Lupus 2012, 21:190-194.
84. Zandman-Goddard G., Shoenfeld Y. Hyperferritinemia in autoimmunity. Isr Med Assoc J 2008, 10:83-84.
85. Yildirim K., Karatay S., Melikoglu M.A., Gureser G., Ugur M., Senel K. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004, 34:423-426.
86. Beyan E., Beyan C., Demirezer A., Ertugrul E., Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol 2003, 32:225-228.
87. De Santis M., Selmi C. The therapeutic potential of epigenetics in autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:92-101.
88. Leung P.S., Wang J., Naiyanetr P., Kenny T.P., Lam K.S., Kurth M.J., et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 2013, 41:79-86.
89. Peters J.M. Proteasomes: protein degradation machines of the cell. Trends Biochem Sci 1994, 19:377-382.
90. Quartuccio L., Rupolo M., Michieli M., De Vita S. Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology 2014, 53:381-382.
91. Schall N., Page N., Macri C., Chaloin O., Briand J.P., Muller S. Peptide-based approaches to treat lupus and other autoimmune diseases. J Autoimmun 2012, 39:143-153.
92. Yu H.C., Lu M.C., Li C., Huang H.L., Huang K.Y., Liu S.Q., et al. Targeted delivery of an antigenic peptide to the endoplasmic reticulum: application for development of a peptide therapy for ankylosing spondylitis. PLoS One 2013, 8:e77451.
93. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 2012, 11:792-794.
94. Miescher S.M., Kasermann F. The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease. Autoimmun Rev 2013, 12:639-642.